Last edition
News about "immune mediated diseases"
Sanofi, Regeneron Expand Alliance to Develop Four Long-Acting Antibodies
Sanofi and Regeneron expands their antibody collaboration to develop and commercialise four next-generation long-acting antibodies for immune-mediated diseases.
Immune-mediated Diseases | 03/10/2026 | By News Bureau | 101
Aethlon Medical to Merge with North Immunology in All-Stock Deal
Aethlon Medical and North Immunology plan to combine through an all-stock merger, backed by an approximately USD 180 million private placement to advance NOR-101 into clinical development.
Immune-mediated Diseases | 18/09/2026 | By News Bureau
Johnson & Johnson Partners with Sail Biomedicines to Advance In Vivo CAR-T Therapies
Johnson & Johnson has entered into a collaboration with Sail Biomedicines to develop in vivo CAR-T therapies for immune-mediated diseases that includes a USD 465 million equity investment, milestone-based payments and an exclusive option to acquire Sail Biomedicines for USD 2.58 billion.
Immune-mediated Diseases | 31/07/2026 | By News Bureau | 151
Innovent Biologics Licenses Anti-CD40L Therapy IBI355 to Spero Therapeutics in USD 1.1 Billion Deal
Innovent Biologics has licensed global rights outside Greater China for its anti-CD40L antibody IBI355 to Spero Therapeutics in a deal valued at up to USD 1.1 billion, advancing the development of a potential new treatment for autoimmune diseases including IgG4-related disease and Sjögren's disease.
Immune-mediated Diseases | 15/07/2026 | By News Bureau | 241
Biogen to Acquire RayThera in Deal Worth Up to USD 1 Billion to Strengthen Immunology Pipeline
Biogen has agreed to acquire immunology-focused biotech firm RayThera in a deal worth up to USD 1 billion, gaining a portfolio of anti-inflammatory drug candidates and strengthening its pipeline for immune-mediated diseases.
Immune-Mediated Diseases | 20/06/2026 | By News Bureau | 184
Japan Grants Orphan Drug Designation to Sanofi's Rilzabrutinib
Sanofi’s rilzabrutinib has received Orphan Drug Designation in Japan for IgG4-related disease (IgG4-RD), supported by positive phase-II study results. The decision marks the therapy’s third global orphan designation in this indication, underscoring Sanofi’s continued focus on advancing treatments for rare immune-mediated diseases.
Immune-mediated Diseases | 02/03/2026 | By News Bureau | 219
Biocon Biologics Secures Global Rights to Hulio
The new agreement supersedes the existing collaboration agreement between Biocon Biologics and Fujifilm Kyowa Kirin Biologics (FKB) for biosimilar Adalimumab, under which Biocon Biologics only had commercialisation rights.
Immune-mediated Diseases | 23/12/2025 | By News Bureau | 315
UPLIZNA Becomes First and Only FDA-Approved Therapy for IGG4-Related Disease
The FDA granted Breakthrough Therapy Designation to UPLIZNA for the treatment of IgG4-RD, recognising the high unmet medical need in this serious condition and the medicine's potential to benefit patients.
Immune Mediated Diseases | 05/04/2025 | By Abha | 467
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy